Herceptin Heart Danger Stays Same Aft...

Herceptin Heart Danger Stays Same After Five Years

There are 5 comments on the Health Scout story from Jun 4, 2007, titled Herceptin Heart Danger Stays Same After Five Years. In it, Health Scout reports that:

“A model of prediction of risk for heart failure was developed that could support a more individualized assessment of cardiac risk”

The chances of developing congestive heart failure as a result of using Herceptin in early-stage breast cancer treatment does not increase over time, new research finds. via Health Scout

Join the discussion below, or Read more at Health Scout.

Since: Dec 05

Vero Beach, FL

#1 Jun 4, 2007
A number of issues on the subject of Herceptin

There are a number of issues on the subject of Herceptin. In addition to taking this drug for a long time, these kind of individual, targeted oral drugs would be taken in addition to an existing repertoire of chemotherapy mixtures a cancer patient is already taking, instead of taking them alone. Adding even more potential toxicities and thousands of dollars to treatment.

Overt congestive heart failure is a very late and serious manifestation of heart muscle damage. For every patient with frank congestive heart failure, there is probably another two, three, four or five patients with heart muscle damage short of congestive heart failure. The sort of heart muscle damage which can cause fatigue and/or shortness of breath with moderate or mild exertion, which otherwise wouldn't occur.

We don't know what will happen 10 or 20 years from now in women who didn't need any adjuvant therapy at all, who would have been cured by surgery alone. Only a minority of patients who receive adjuvant therapy benefit from it. Adjuvant therapy is worth it if the women have to suffer only short term, temporary toxicity, and if it even slightly reduces the probability that their cancers will come back. But if it produces permanent toxicity, whether "chemo brain" or "heart muscle damage," that is a whole different order of magnitude in terms of risk.

Aside from the issue of congestive heart failure, past studies have suggested a potentially very serious weakness in the drug, the problem with central nervous system (CNS) metastasis. A study from the Dana Farber Cancer Institute identified central nervous system (CNS) metastases in women who receive trastuzumab-based (Herceptin) therapy for metastatic breast carcinoma. Central nervous system disease is defined as one or more brain metastases or leptomeningeal carcinomatosis (carcinomatous meningitis).

Central nervous system metastases was identified in 34% of patients at a median of 16 months after diagnosis of metastatic breast cancer and 6 months from the beginning of Herceptin treatment. Patients receiving Herceptin as first-line therapy for metastatic disease frequently developd brain metastases while responding to or stable on Herceptin. The authors of the study say that efforts to characterize other risk factors for development of CNS disease, optimal screening algorithms, and new treatment strategies may be warranted.

The potential benefits and risks of Herceptin have renewed concerns about the reliability of HER2 testing. Some studies have shown that the test produces false positives as often as 26% of the time, and may also carry some risk of false negatives. Herceptin also doesn't offer any benefit to women with HER2-negative cancer.

Lastly, monoclonal antibodies like Herceptin (and Erbitux) are "large" molecules. These very large molecules don't have a convenient way of getting access to the large majority of cells. Plus, there is multicellular resistance, the drugs affecting only the cells on the outside may not kill these cells if they are in contact with cells on the inside, which are protected from the drug. The cells may pass small molecules back and forth.

Exciting results have come from studies of multitargeted tyrosine kinase inhibitors,"small" molecules that act on multiple receptors in the cancerous cells, like Tyberb and Sutent. Targeted "small-molecule" therapies ruled at last years annual ASCO meeting of oncologists. The trend is away from the monoclonals to the small molecules, a trend in which a new predictive test may be able to hasten (The EGFRx Assay).

(Cancer 2003 Jun 15;97(12):2972-7)
Grannyfatandtatt le

Crossville, TN

#2 May 24, 2008
Its time to wake up! ACT treatment complete and about 6 months of weekly Herceptin treatment. Now how are you doing? Well I have this major problem and Doc says it NOT a side effect of medicine. Its not a simple problem, you see its a circulation problem in my neck. The feeling of having a blood pressure cuff around your neck. When I bend over or over exert myself there is a rush of blood to my head and it takes time for the flow to relax and settle down. Painful? No
Annoying? Yes
Well after stress test, CT test of chest I just accepted the problem. Well the pressure is worse, so once again I confronted the situation and I now have a appointment with vascular surgeon. The problem is supposedly a blocked jugular vein. Blocked by what I am not sure. Possible a blood clot? Well until my appt, which is 10 days away, I won't know. So I put up with this since christmas, so whats 10 more days.
Warning on herceptin says possibility of blood clots. Heres Your Sign!
I will stop the treatments!!!! Duh!!!

Since: Dec 05

Irvington, NJ

#3 May 24, 2008
Many of these new "targeted" therapies often get a pass on toxicities because they are just so darn cool. The problem is that few drugs work the way oncologists think and few of them take the time to think through what it is they are using them for.

The Dr. Katharina Pachmann, et al study in the May 2005 issue of Oncology News International reported that Taxol can cause the release of cancer cells into the blood. I'm not so sure that Herceptin is taking care of what Taxol never accomplished in the first place, reducing circulating tumor cells in patients.

Medford, NY

#4 Dec 10, 2011
Well I was put on perception in addition to chemo for six months before I became symptomatic. I felt like I swam and swallowed water. Turned out I have interstitial lung disease. It scarred my Lungs and it is not getting better.
Pleiase do yor reachearch before you begin..there are no sure benefits from this drug. Very serious side effects.
#5 Sep 23, 2013
I have ordered 2 times from this website PILLSMEDSHOP. COM . I called yesterday the customer care and asked for a discount as i was about to order twice the regular amount.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Breast Cancer Discussions

Title Updated Last By Comments
News Donna Deegan: Why the name change? (Dec '07) Feb 13 Janie 59
I'm scared I might have male breast cancer =(!(... (Oct '06) Feb 8 kiran rai 885
News Drugs firms profiteer from NHS by hiking cancer... Jan 30 Holy Silicon Wafer 1
News Fighting Breast Cancer - What You Can Do (Oct '11) Jan '17 LeroyMorris 8
Am free from breast cancer. (Nov '14) Jan '17 LeroyMorris 4
News Plastic surgery's affordable to all (Apr '06) Jan '17 watson983 177
Taxotere - side effects - permanent hair loss ! (Mar '09) Jan '17 Boo 367
More from around the web